rev: October 29, 2003
HOME (index HOME page)
Return (anti-mouse CD antibody index page)
CD CLUSTERED ANTIBODIES
RDI Divison of Fitzgerald Industries Intl offers a wide line of antibodies. Since no one antibody works best for all applications (flow cytometry, neutralization, blotting, histochemistry, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below. All products are for in vitro research use only-not for use in or on humans or animals-not for use in diagnostics. Price/availability/specifications subject to change without notice.
DATA SHEET: -see also anti-mouse CD45.1, CD45.2, CD45R, CD45RA, CD45RB, CD45RC y
Catalog#: RDI-mCD45R-RA Price: $281.00/1pkg
also available PE conjugated: cat#RDI-MCD45R-RAPE $594.00/0.2mg
FITC conjugated cat#RDI-MCD45R-RAFT $625.00/0.5mg
Biotin conjugated cat#RDI-MCD45R-RABT $625.00/0.5mg
azide free: cat#RDI-MCD45R-RAXP $625.00/0.5mg
Package Size: purfified antibody in PBS with 0.09% sodium azide
Ig Isotype: rat IgG2ak
Immunogen: Abelson murine leukemia virus induced pre-B tumor cells
Uses: This antibody has been tested by immunofluorescent staining (1 µg/million cells) with flow cytometric analysis to assure specificity and reactivity. Other reported applications include immunohistochemical staining (IHC) of acetone-fixed frozen and formalin- or zinc-fixed paraffin-embedded sections,(16) immunoprecipitation (1)and modulation of B-cell responses in vitro and in vivo.(13,14,15) Since applications vary, each investigator must determine dilutions appropriate for individual use.
Storage: Store at 4 Deg C.
Precautions: For In vitro research Use Only. Not for use in or on humans or animals or for diagnostics. Sodium azide may form explosive compounds in presence of heavy metals or under acidic conditions. Flush drains with copious amounts of water to prevent buildup of explosive compounds.
The RA3-6B2 antibody reacts with an epitope on the extracellular domain of CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues.2 It is expressed on B lymphocytes at all stages from pro-B through mature and activated B cell (,1,2,3,4) and levels of expression of CD45R/B220 on the B-cell lineage appear to be developmentally regulated.(3,4,5) It is also found on the abnormal T cells involved in the lymphadenopathy of lpr/lpr (6) and gld/gld (7) mutant mice, on lytically active subsets of lymphokine-activated killer cells (NK cells and non-MHC-restricted CTL),8 on apoptotic T lymphocytes of mice injected with bacterial superantigen,9 on a population of NK-cell precursors in the bone marrow,10 and on B-lymphocyte, T-lymphocyte, and macrophage progenitors in fetal liver.11 The CD45R/B220 antigen is not on hematopoietic stem cells, plasma cells, T lymphocytes, or MHC-restricted CTL. CD45 is a member of the Protein Tyrosine Phosphatase (PTP) family: Itsintracellular (COOH-terminal) region contains two PTP catalytic domains, and the extracellular region is highly variable due to alternative splicing of exons 4, 5, and 6 (designated A, B, and C, respectively), plus differing levels of glycosylation.(2) The CD45 isoforms detected in the mouse are cell type-, maturation-, and activation state-specific.2 The CD45 isoforms play complex roles in T-cell and B-cell antigen receptor signal transduction.(2) CD45R/B220 is commonly used as a pan B-cell marker; however, CD19 expression, detected by mAb 1D3, is reported to be more restricted to the B-cell lineage.(12) mAb RA3-6B2 has been reported to enhance isotype switching during in vitro B-cell responses (13) and to inhibit in vivo B-cell responses.(14,15)
For Research Use Only. Not For Diagnostic or Therapeutic Use.
1. Coffman, R.L. 1982. Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development. Immunol. Rev. 69: 5 - 23.
2. Johnson, P., A. Maiti, and D.H.W. Ng. 1997. CD45: A family of leukocyte-specific cell surface glycoproteins. In Weirs Handbook of Experimental Immunology, Vol. 2. L.A. Herzenberg, D.M. Weir, L.A. Herzenberg, and C. Blackwell, eds. Blackwell Science, Cambridge, MA, pp. 62.1 - 62.16.
3. Hardy, R.R., C.E. Carmack, S.A. Shinton, J.D. Kemp, and K. Hayakawa. 1991. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J. Exp. Med. 173: 1213 - 1225.
4. Hathcock, K.S., H. Hirano, S. Murakami, and R.J. Hodes. 1992. CD45 expression by B cells. Expression of different CD45 isoforms by subpopulations of activated B cells. J. Immunol. 149: 2286 - 2294.
5. Allman, D.M., S.E. Ferguson, and M.P. Cancro. 1992. Peripheral B cell maturation. I. Immature peripheral B cells in adults are heat-stable antigen hi and exhibit unique signaling characteristics. J. Immunol. 149: 2533 - 2540.
6. Laouar, Y., and S. Ezine. 1994. In vivo CD4 + lymph node T cells from lpr mice generate CD4 - CD8 - B220 + TCR-â low cells. J. Immunol. 153: 3948- 3955.
7. Kobata, T., K. Takasaki, H. Asahara, N.M. Hong, K. Masuko-Hongo, T. Kato, S. Hirose, T. Shirai, N. Kayagaki, H. Yagita, K. Okumura, and K. Nishioka. 1997. Apoptosis with FasL + cell infiltration in the periphery and thymus of corrected autoimmune mice. Immunology 92: 206 213.
8. Ballas, Z.K., and W. Rasmussen. 1993. Lymphokine-activated killer cells VII. IL-4 induces an NK1.1 + CD8 + â - TCR-áâ B220 + lymphokine-activated killer subset. J. Immunol. 150: 17 - 30.
9. Renno, T., M. Hahne, J. Tschopp, and H.R. MacDonald. 1996. Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J. Exp. Med. 183: 431 437.
10. Rolink, A., E. ten Boekel, F. Melchers, D.T. Fearon, I. Krop, and J. Andersson. 1996. A subpopulation of B220 + cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors. J. Exp. Med. 183: 187 194.
11. Sagara, S., K. Sugaya, Y. Tokoro, S. Tanaka, H. Takano, H. Kodama, H. Nakauchi, and Y. Takahama. 1997. B220 expression by T lymphoid progenitor cells in mouse fetal liver. J. Immunol. 158: 666 676.
12. Krop, I., A.R. de Fougerolles, R.R. Hardy, M. Allison, M.S. Schlissel, D.T. Fearon. 1996. Self-renewal of B-1 lymphocytes is dependent on CD19. Eur. J. Immunol. 26: 238 - 242.
13. George, A., S. Rath, K.E. Shroff, M. Wang, and J.M. Durdik. 1994. Ligation of CD45 on B cells can facilitate production of secondary Ig isotypes. J. Immunol. 152: 1014 - 1021.
14. Asensi, V., K. Kimeno, I. Kawamura, M. Sakumoto, and K. Nomoto. 1989. Treatment of autoimmune MRL/lpr mice with anti-B220 monoclonal antibody reduces the level of anti-DNA antibodies and lymphadenopathies. Immunology 68: 204 - 208.
15. Domiati-Saad, R., E.W. Ogle, and L.B. Justement. 1993. Administration of anti-CD45 mAb specific for a B cell-restricted epitope abrogates the B cell reponse to a T-dependent antigen in vivo. J. Immunol. 151: 5936 - 5947.
16. Unpublished results.
For Research Use Only. Not For Diagnostic or Therapeutic Use.
It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. We are not responsible for any patent infringements that might result with the use of or derivation of this product.
34 Junction Square Drive
Concord MA 01742-3049
phone (978) 371-6446 or (800) 370-2222
fax (978) 371-2266